Warning Letter — Royal Peptides LLC
The FDA issued a warning letter to Royal Peptides LLC regarding the marketing and sale of unapproved and misbranded drug products. The Center for Drug Evaluation and Research (CDER) identified regulatory violations following an evaluation of the firm's operations.
This action affects Royal Peptides LLC, as well as regulatory and compliance departments within companies distributing peptide-based products or chemicals marketed with therapeutic claims.
This enforcement action underscores the FDA's continued focus on firms marketing unapproved substances, particularly peptides, through direct-to-consumer or online channels. It suggests that companies operating in this space must ensure their products do not meet the statutory definition of a drug through intended use claims without obtaining the necessary market authorizations. Failure to rectify these violations may lead to further enforcement actions such as seizure or injunction.
Review all web-based product listings and marketing materials to ensure no therapeutic claims are made for unapproved drug products. Verify that any research-use-only chemicals are not being marketed or sold for human consumption or therapeutic purposes. Establish a rigorous regulatory review process for all consumer-facing digital content.
FDA Warning Letter issued to: Royal Peptides LLC. 08/24/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026
Open in openFDA / FDA.gov